DM Full Guideline (2010) - VA/DoD Clinical Practice Guidelines Home

More documents

Recommendations

Info

Version 4.0 VA/DoD Clinical Practice Guideline for the Management of Diabetes Mellitus Golightly LK, Jones MA, Hamamura DH et al. Management of diabetes mellitus in hospitalized patients: efficiency and effectiveness of sliding-scale insulin therapy. Pharmacotherapy 2006; 26(10): 1421-32. Goudswaard AN, Furlong NJ, Rutten GE et al. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2004(4): CD003418. Gray CS, Hildreth AJ, Sandercock PA et al. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 2007; 6(5): 397-406. Grey NJ, Perdrizet GA. Reduction of nosocomial infections in the surgical intensive-care unit by strict glycemic control. Endocr Pract 2004; 10(Suppl 2): 46-52. Griesdale DE, de Souza RJ, van Dam RM et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 2009; 180(8): 821-7; discussion 799- 800. Hansen HP, Gaede PH, Jensen BR et al. Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria. Diabetes Care 2000; 23(12): 1742-5. Harding SP, Broadbent DM, Neoh C, White MC, Vora J. Sensitivity and specificity of photography and direct ophthalmoscopy in screening for sight threatening eye disease: the Liverpool Diabetic Eye Study. BMJ. 1995 Oct 28;311(7013):1131-5. Harris MI. Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24(6): 979-82. Heine RJ, Van Gaal LF, Johns D et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143(8): 559-69. Herman WH, Dungan KM, Wolffenbuttel BH et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab 2009; 94(5): 1689-94. Herman WH, Ilag LL, Johnson SL et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005; 28(7): 1568-73. Herman WH, Ma Y, Uwaifo G et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care 2007; 30(10): 2453-7. Hermansen K, Davies M, Derezinski T et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29(6): 1269-74. Hermansen K, Kipnes M, Luo E et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9(5): 733-45. Hirsch IB, Bode BW, Garg S et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 2005; 28(3): 533-8. Holewski JJ, Stess RM, Graf PM et al. Aesthesiometry: quantification of cutaneous pressure sensation in diabetic peripheral neuropathy. J Rehabil Res Dev 1988; 25(2): 1-10. Hollander P, Li J, Allen E et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009; 94(12): 4810-9. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577-89. Hoogma RP, Hammond PJ, Gomis R et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med 2006; 23(2): 141-7. Horvath K, Jeitler K, Berghold A et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 20072): CD005613. Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med 2006; 355(18): 1903-11. Appendices Page 137
Version 4.0 VA/DoD Clinical Practice Guideline for the Management of Diabetes Mellitus Ishihara M, Inoue I, Kawagoe T et al. Is admission hyperglycaemia in non-diabetic patients with acute myocardial infarction a surrogate for previously undiagnosed abnormal glucose tolerance? Eur Heart J 2006; 27(20): 2413-9. Jaber R, Braksmajer A, Trilling JS. Group visits: a qualitative review of current research. J Am Board Fam Med 2006; 19(3): 276-90. Jacobson JM, O'Rourke PJ, Wolf AE. Impact of a diabetes teaching program on health care trends in an Air Force Medical Center. Mil Med 1983; 148(1): 46-7. Janka HU, Plewe G, Riddle MC et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28(2): 254-9. Jansen JP. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Curr Med Res Opin 2006; 22(4): 671-81. Javitt JC, Aiello LP, Chiang Y et al. Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes Care 1994; 17(8): 909-17. Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 1996; 124(1 Pt 2): 164-9. Javitt JC, Canner JK, Sommer A. Cost effectiveness of current approaches to the control of retinopathy in type I diabetics. Ophthalmology 1989; 96(2): 255-64. Jeitler K, Horvath K, Berghold A et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008; 51(6): 941-51. Joint Commission Inpatient Diabetes Care Certification: Management of the Patient with Diabetes in the Inpatient Setting. Oakbrook Terrace, IL: Joint Commission on Accreditation of Healthcare Organizations 2010: Mar 1. Available at http://www.jointcommission.org/NR/rdonlyres/F9B67C2-72A6-4DC3-A047- 15BEB394FE3C/0/Diabetes_Addendum.pdf. JNC 7 - The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda MD: National Institutes of Health, National Heart Lung and Blood Institute, National High Blood Pressure Education Program (NIH Publication No 04-5230). 2004: p. 1-86. Available at : http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf. Kagansky N, Levy S, Rimon E et al. Hypoglycemia as a predictor of mortality in hospitalized elderly patients. Arch Intern Med 2003; 163(15): 1825-9. Kansagara D, Wolf F, Freeman M, Helfand M. Management of inpatient hyperglycemia: a systematic review. Portland, OR: Portland Veterans Affairs Healthcare System, Oregon Evidence-based Practice Center. 2008: i-viii; 1-55. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28(5): 1083-91. Kim HS, Oh JA. Adherence to diabetes control recommendations: impact of nurse telephone calls. J Adv Nurs 2003; 44(3): 256-61. King AB, Wolfe GS. Evaluation of a diabetes specialist-guided primary care diabetes treatment program. J Am Acad Nurse Pract 2009; 21(1): 24-30. Kirsh S, Watts S, Pascuzzi K et al. Shared medical appointments based on the chronic care model: a quality improvement project to address the challenges of patients with diabetes with high cardiovascular risk. Qual Saf Health Care 2007; 16(5): 349-53. Klein R, Klein BE, Moss SE et al. The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 1994; 112(9): 1217-28. Klein R, Klein BE, Moss SE et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984a; 102(4): 520-6. Klein R, Klein BE, Moss SE et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984b; 102(4): 527-32. Appendices Page 138
Page 2 and 3:
VA/DoD CLINICAL PRACTICE GUIDELINE
Page 4 and 5:
Version 4.0 VA/DoD Clinical Practic
Page 6 and 7:
Page 8 and 9:
Page 10 and 11:
Page 12 and 13:
Version 4.0 ALGORITHM VA/DoD Clinic
Page 14 and 15:
Version 4.0 MODULE D - CORE ANNOTAT
Page 16 and 17:
Version 4.0 B. Refer To Pediatric D
Page 18 and 19:
Version 4.0 E. Is the Patient Medic
Page 20 and 21:
Version 4.0 Evaluation Component VA
Page 22 and 23:
Version 4.0 H. Consider Aspirin The
Page 24 and 25:
Page 26 and 27:
Version 4.0 Table D5. Target Level
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Version 4.0 ALGORITHM VA/DoD Clinic
Page 36 and 37:
Version 4.0 Table S-1. Risk Factors
Page 38 and 39:
Version 4.0 EVIDENCE VA/DoD Clinica
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Version 4.0 7. A combination of pre
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Version 4.0 EVIDENCE VA/DoD Clinica
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Version 4.0 J-1. MONOTHERAPY (Initi
Page 58 and 59:
Version 4.0 EVIDENCE TABLE VA/DoD C
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Version 4.0 Insulin Dosing Examples
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Version 4.0 RATIONALE VA/DoD Clinic
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Version 4.0 RECOMMENDATIONS VA/DoD
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89: Version 4.0 Comparison of Insulin P
Page 90 and 91: Version 4.0 ALGORITHM VA/DoD Clinic
Page 92 and 93: Version 4.0 VA/DoD Clinical Practic
Page 94 and 95: Version 4.0 EVIDENCE VA/DoD Clinica
Page 98 and 99: Version 4.0 ANNOTATIONS VA/DoD Clin
Page 104 and 105: Version 4.0 EVIDENCE - Take Charge
Page 110 and 111: Version 4.0 o Evaluation of the pat
Page 120 and 121: Version 4.0 General principles to b
Page 126 and 127: Version 4.0 Algorithm Format VA/DoD
Page 128 and 129: Version 4.0 President Healthcare Qu
Page 132 and 133: Version 4.0 SMBG SME SUD TC TDD TDI
show all

DM Full Guideline (2010) - VA/DoD Clinical Practice Guidelines Home

Create successful ePaper yourself

Delete template?

Save as template?